2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãß°èÇмú´ëȸ°¡ Áö³ 2024³â 8¿ù 30ÀϺÎÅÍ 31ÀϱîÁö ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÄÁº¥¼Ç¼¾ÅÍ¿¡¼ ÁøÇàµÇ¾ú´Ù. À¯³È÷ ´õ¿ü´ø À۳⠿©¸§ÀÇ ´õÀ§°¡ °¡½ÃÁö ¾ÊÀº ³¯¾¾¿¡ °¡À»ÇÐȸ°¡ °³ÃֵǾúÁö¸¸ Áö¼ÓµÇ´Â ÀÇÁ¤»çÅ¿¡µµ ºÒ±¸ÇÏ°í ¸¹Àº ȸ¿øµéÀÌ Âü¿©ÇÏ¿© ¼ºÈ²¸®¿¡ ÇмúÇà»ç°¡ ÁøÇàµÇ¾ú´Ù.
ù°³¯ °¿¬¿¡¼´Â Thyroid Hormone and Fertility ÁÖÁ¦·Î ³»°ú ¹× »êºÎÀΰú ¿¬ÀںеéÀ» ÃÊûÇÏ¿© ´ÙÇÐÁ¦ÀûÀÎ Á¢±Ù¿¡ ´ëÇÑ °¿¬À¸·Î ½ÃÀÛÇÏ¿´À¸¸ç Medullary Thyroid Cancer¿¡ ´ëÇÑ ³»¿Ü°úÀû ÃֽŠÁö°ßÀ» ´Ù·ç´Â ¼¼¼ÇÀÌ À̾îÁ³´Ù.
ƯÈ÷ Meet the Professor1 ¼¼¼Ç¿¡¼ ¿À·£¸¸¿¡ Gregory A. Brent (David Geffen School of Medicine at UCLA, USA) ±³¼ö°¡ Çѱ¹À» ¹æ¹®ÇÏ¿© °¿¬À» ÇÏ¿´À¸¸ç µ¿ ½Ã°£´ë¿¡ Meet the Professor2 ¼¼¼Ç¿¡¼ 20 Year Experience in Thyroid Intervention¶ó´Â Á¦¸ñÀ¸·Î ¿ï»êÀÇ´ë ¹éÁ¤È¯ ±³¼ö°¡ °¿¬ÇÏ¿´À¸¸ç ±×µ¿¾È ½×¾Æ¿Â ÀÓ»ó °æÇè°ú ¿¬±¸ ¾÷ÀûÀ» ȸ¿øµé°ú °øÀ¯ÇÏ´Â ÀÚ¸®°¡ µÇ¾ú´Ù.
¿¬±¸À§¿øȸ¼¼¼Ç¿¡¼´Â ¡°°©»ó¼± Áúȯ ´Ù±â°ü ¹«ÀÛÀ§¹èÁ¤ Àӻ󿬱¸ÀÇ ¹æ¹ý·Ð°ú ½ÇÁ¦¡±¶ó´Â ÁÖÁ¦·Î ÇöÀç ÁøÇàµÇ´Â °©»ó¼±ºÐ¾ßÀÇ RCT »ç¾÷À» ¼Ò°³ÇÏ°í ÇâÈÄ ¿¬±¸ÀÇ È°¼ºÈ¸¦ À§ÇÑ ¹æ¹ý·Ð¿¡ °üÇÏ¿© ±íÀÌ ÀÖ´Â Åä·ÐÀÌ À̾îÁ³´Ù.
ÇÐȸ µÑ° ³¯ Gregory A. Brent ±³¼öÀÇ plenary lecture°¡ ÀÖ¾úÀ¸¸ç ±×µ¿¾ÈÀÇ ¿À·£ ÇмúÀûÀÎ ¼ºÃë¿Í ÇÔ²² Çѱ¹°úÀÇ °³ÀÎÀûÀÎ Àο¬ ¹× °¡Á·»ç¿¡ ´ëÇؼ ¼Ò°³ÇÏ´Â ÈÆÈÆÇÑ ½Ã°£ÀÌ µÇ¾ú´Ù.
Thyroid Cancer Survivorship Care ¼¼¼Ç¿¡¼´Â °©»ó¼±¾ÏÀÇ ¼ö¼ú ÈÄ ¸ð´ÏÅ͸µ°ú µ¿¹ÝÁúȯ, QoL °ü¸®¿¡ À̸£±â±îÁö ÃֽŠ¿¬±¸°á°ú¿Í Ä¡·á Æ®·»µå¿¡ °üÇÑ °¿¬ÀÌ ÀÖ¾úÀ¸¸ç Up-to date of Hyperthyroidism Management ¼¼¼Ç¿¡¼´Â °©»ó¼±±â´ÉÇ×ÁøÁõÀÇ ¾à¹°, ¼ö¼ú, ¹æ»ç¼º¿ä¿ÀµåÄ¡·á µîÀÇ ÃֽŠÀ̽´¿¡ °üÇÑ Àü¹®°¡ °ÀÇ°¡ À̾îÁ³´Ù.
ÃÑȸ¿¡¼´Â ¼º±Õ°üÀÇ´ë ¿Ü°ú ±èÁö¼ö ±³¼ö°¡ 2025³â ȸÀåÀ¸·Î Ãß´ëµÇ¾úÀ¸¸ç À̾îÁö´Â Presidential Lecture¿¡¼ Challenging Issues Toward a Unified Ultrasound Risk Stratification System for Thyroid Nodules¶ó´Â ÁÖÁ¦·Î 2024³â ³ªµ¿±Ô (¿ï»êÀÇ´ë ¿µ»óÀÇÇаú) ȸÀåÀÇ °¿¬ÀÌ ÀÖ¾ú´Ù.
À̾îÁö´Â ¿ÀÈÄ ½Ã°£¿¡´Â US Guided Interventional Management of Benign Thyroid and Neck Lesions ¼¼¼Ç¿¡¼ ÃÖ±Ù °ü½ÉÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °©»ó¼±Á¾¾çÀÇ ºñ¼ö¼úÀû Ä¡·á¿¡ ´ëÇÑ ´Ù°¢µµÀÇ °¿¬ÀÌ ÀÖ¾úÀ¸¸ç Áø·áÁöħÁ¦Á¤À§¿øȸ ¼¼¼ÇÀº ¡°KTA Áø·á±Ç°í¾ÈÀÇ ½ÇÁ¦ ÀÓ»ó Àû¿ë¡±À̶ó´Â ÁÖÁ¦·Î ½ÇÁ¦ Áõ·Ê¿¡ °üÇÑ Ã»Áß ÅõÇ¥¸¦ ÁøÇàÇÏ¿© Èï¹Ì¸¦ ²ø¾ú´Ù. KTA Á¤Ã¥ ¿¬±¸ °úÁ¦: °©»ó¼± °áÀý ¼±º°°Ë»ç¿¡ ´ëÇÑ È¿¿ë¼º ¿¬±¸ ¼¼¼Ç¿¡¼´Â ÁÖ¿ä ÀïÁ¡ÀÌ µÇ°í ÀÖ´Â Key Questionº°·Î ±Ù°Å Á᫐ ¿¬±¸ °á°ú¸¦ ¹ÙÅÁÀ¸·Î ½Éµµ ÀÖ´Â ³íÀÇ°¡ ÁøÇàµÇ¾ú´Ù.
ÀÌ¿Í ÇÔ²² ÀÇÁ¤»çÅ·Π¾î·Á¿î ȯ°æ¿¡¼µµ Free Paper ¼¼¼Ç¿¡ ¸¹Àº ȸ¿øµéÀÇ ÃÖ±Ù ¿¬±¸ °á°ú°¡ ¹ßÇ¥ µÇ¾î Å« °ü½É°ú Åä·ÐÀÇ ±âȸ°¡ ÀÖ¾ú´Ù.
<´ëÇÑ°©»ó¼±ÇÐȸ 2024 Ãß°èÇмú´ëȸ ¼ö»ó ³»¿ª>
±¸ºÐ | ¿¬±¸ Á¦¸ñ | ¼º¸í | ¼Ò¼Ó |
---|---|---|---|
¿ì¼ö ¿¬±¸ÀÚ»ó | Development of technology to predict progression of papillary thyroid microcarcinoma using mitochondrial DNA | Á¶¿µ¼® | ¿¬¼¼ÀÇ´ë ³»°ú |
ÀþÀº ¿¬±¸ÀÚ»ó | Analysis of Oral and Gut microbiomes Changes according to Hashimoto Thyroiditis following Thyroidectomy | ±èÈñÁØ | Â÷ÀÇ°ú´ë ¿Ü°ú |
±âÃÊÀÇÇבּ¸»ó | A Role of CHI3L1 in Orbital Fibroblast of Thyroid Eye Disease | ÀÓµ¿ÁØ | °¡Å縯ÀÇ´ë ³»°ú |
Discovery of new therapies targeting the resistant mechanism of dabrafenib/trametinib combination treatment in thyroid cancer | Àü¹ÎÁö | ¿ï»êÀÇ´ë ³»°ú | |
ÃÖ¿ì¼ö³í¹®»ó | ¿©´ü °¡Áö ½Ã¾àÀ¸·Î ÃøÁ¤ÇÑ Ç÷û °©»ó¼±ÀÚ±ØÈ£¸£¸ó °á°ú°ª Â÷ÀÌ: ¹«Áõ»ó°©»ó¼±±â´ÉÀúÇÏÁõ Áø·áÁöħÀÇ ÀÓ»ó Àû¿ëÀ» À§ÇÑ Âü°í±¸°£ ºñ±³ ¿¬±¸ | À¯¿ø»ó, ±è¼ÖÀÙ/ Á¤Çö°æ, ÆØÁøö |
´Ü±¹ÀÇ´ë ³»°ú, ¿ï»êÀÇ´ë Áø´Ü°Ë»çÀÇÇаú/ ´Ü±¹ÀÇ´ë ³»°ú, ¼¿ïÀÇ´ë ÇÙÀÇÇаú |
The Role of De novo Serine Biosynthesis from Glucose in Papillary Thyroid Cancer | À̼ºÀº/ °¿¹Àº, ±¸º»¼® |
Ãæ³²ÀÇ´ë/ Ãæ³²ÀÇ´ë ³»°ú, À̺ñÀÎÈÄ°ú |
|
¿ì¼ö³í¹®»ó | Artificial Intelligence Computer-Assisted Diagnosis for Thyroid Nodules: Comparison of Diagnostic Performance Using Original and Mobile Ultrasonography Images | Á¶»ó¿ì/°ûÁø¿µ | ¿¬¼¼ÀÇ´ë/¿¬¼¼ÀÇ´ë ¿µ»óÀÇÇаú |
Effects of Isthmus Preservation on Postoperative Hypothyroidism after Lobectomy | Àü¿µ»ê/±è¿Ï¿í | ±¸º´¿ø ¿Ü°ú/»ïÀϺ´¿ø ¿Ü°ú | |
±¹Á¦ÇÐȸ³í¹®»ó | BRAF mutation is associated with tumor volume doubling time of papillary thyroid microcarcinoma during active surveillance | ±èÁø¿µ | °¡Å縯ÀÇ´ë ³»°ú |
Clinical Practice Guidelines for Radiofrequency Ablation of Benign Thyroid Nodules and Malignant Thyroid Cancers: A Systematic Review | À̹ΰæ | °¡Å縯ÀÇ´ë ¿µ»óÀÇÇаú | |
Impact of additional computed tomography in patients with low-risk papillary thyroid microcarcinoma eligible for active surveillance | Àü¿µÈÆ | ¼¿ïÀÇ´ë ¿µ»óÀÇÇаú | |
Serum anti-thyroglobulin antibody levels following total thyroidectomy are related to the recurrence of papillary thyroid carcinoma | ÀÌÁؼº | ¿¬¼¼ÀÇ´ë ¿Ü°ú | |
Comparative Outcomes of Synchronous Follicular and Papillary Thyroid Cancers: A Retrospective Analysis | ±è³²°æ | ¿¬¼¼ÀÇ´ë ¿Ü°ú | |
ÃÖ¿ì¼ö¿¬Á¦»ó | Deep Learning Model for Preoperative Prediction of Lymph Node Metastasis in Thyroid Cancer Using Whole Slide Images of Core Needle Biopsies | Á¤Âù±Ç | °¡Å縯ÀÇ´ë º´¸®°ú |
¿ì¼ö¿¬Á¦»ó | Impact of additional computed tomography in patients with low-risk papillary thyroid microcarcinoma eligible for active surveillance | Àü¿µÈÆ | ¼¿ïÀÇ´ë ¿µ»óÀÇÇаú |
Early Detection of Medullary Thyroid Carcinoma for Improving Initial Response and Long-Term Survival | À¯ÁöÇö | ¼º±Õ°üÀÇ´ë ³»°ú | |
INITIAL EXPERIENCE OF SINGLE-PORT TRANSAXILLARY ROBOTIC RADICAL NECK DISSECTION(STAR-RND) VIA 3CM INCISION | ±èÁø°æ | ¿¬¼¼ÀÇ´ë ¿Ü°ú | |
Diagnosis and evaluation of aggressiveness using circulating plasma miRNAs in papillary thyroid microcarcinoma | À̺´ÁÖ | ºÎ»êÀÇ´ë À̺ñÀÎÈÄ°ú | |
Impact of fibroblast growth factor receptor (FGFR) inhibition for reinforcing radioactive-iodine (RAI) avidity in thyroid cancers | ¾Èº´Ã¶ | °æºÏÀÇ´ë ÇÙÀÇÇаú | |
¿ì¼öÆ÷½ºÅÍ»ó | A Prospective Clinical Trial of Radiofrequency Ablation in Patients with Low-Risk Unifocal Papillary Thyroid Microcarcinoma favoring Active Surveillance over Surgery | ÀÌÁö¿¹ | ¼¿ïÀÇ´ë ¿µ»óÀÇÇаú |
Unveiling the Impact of BRAFV600E Mutation on Nuclear Invagination via High-Resolution Digital Microscopy | ÀÌÇÏ¿µ | ±¹¸³¾Ï¼¾ÅÍ |